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a b s t r a c t
We have validated a ﬂexible, high-throughput and relatively inexpensive RT-QPCR array platform for
absolute quantiﬁcation of Epstein–Barr virus transcripts in different latent and lytic infection states.
Several novel observations are reported. First, during infection of normal B cells, Wp-initiated latent
gene transcripts remain far more abundant following activation of the Cp promoter than was hitherto
suspected. Second, EBNA1 transcript levels are remarkably low in all forms of latency, typically ranging
from 1 to 10 transcripts per cell. EBNA3A, -3B and -3C transcripts are likewise very low in Latency III,
typically at levels similar to or less than EBNA1 transcripts. Thirdly, a subset of lytic gene transcripts is
detectable in Burkitt lymphoma lines at low levels, including: BILF1, which has oncogenic properties, and
the poorly characterized LF1, LF2 and LF3 genes. Analysis of seven African BL biopsies conﬁrmed this
transcription proﬁle but additionally revealed signiﬁcant expression of LMP2 transcripts.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
Primary infection of resting B cells in vitrowith EBV leads to the
activation of the multimerised Wp promoter and expression of
EBNA2, EBNA-LP and latent BHRF1, followed by activation of a
second promoter Cp and eventually expression of all six EBNAs
(EBNA1, 2, 3A, 3B, 3C and LP) and, from their own promoters, three
latent membrane proteins (LMP1, 2A and 2B) (Amoroso et al.,
2011; Kelly et al., 2009; Rickinson and Kieff, 2007; Tierney et al.,
2011). The non-coding EBERs (Arrand and Rymo, 1982; Lerner et
al., 1981), BARTs (Chen et al., 1999; Gilligan et al., 1990; Sadler and
Raab-Traub, 1995) and a series of miRNAs (Amoroso et al., 2011;
Pfeffer et al., 2004) are also transcribed. This pattern of latent gene
expression, which drives B cell growth transformation and the
establishment of permanently growing lymphoblastoid cell lines
(LCLs), has been classiﬁed as Latency III, or Lat III (Rickinson and
Kieff, 2007; Rowe et al., 1992).
Alternative patterns of viral gene expression have also been
classiﬁed. The most restricted, Latency 0 (Lat 0), is the form found
in circulating B lymphocytes in vivo in healthy virus carriers where
all EBV protein expression is silenced, and only the non-coding
EBERs, BARTs and miRNAs are transcribed. Latency I (Lat I),
identiﬁed in Burkitt lymphoma (BL) biopsies and many derived
BL cell lines (Rowe et al., 1992), is characterized by a lack of Cp/Wp
promoter activity and the expression of a single latent antigen
EBNA1 from the alternate Qp promoter (Nonkwelo et al., 1996;
Schaefer et al., 1995b), along with expression of the non-coding
RNAs. Latency II (Lat II), characteristic of NPC and Hodgkin
lymphoma tumor cells, resembles Lat I but with additional
expression of LMP1 and LMP2 (Brooks et al., 1992; Deacon et al.,
1993). These latency deﬁnitions are not absolute, but represent
points on a spectrum of EBV gene expression which may occur at
different times or different anatomical sites during EBV latency
in vivo (Thorley-Lawson et al., 2013).
In contrast to the limited number of genes expressed in virus
latency, entry into productive lytic cycle results in the temporally
co-ordinated expression of over 80 lytic genes (Kieff and
Rickinson, 2007). The immediate-early (IE) transactivators, BZLF1
and BRLF1 (Feederle et al., 2000; Takada and Ono, 1989), induce
the expression of a number of EBV genes in either a methylation-
dependent or methylation-independent manner (Bergbauer et al.,
2010; Ramasubramanyan et al., 2012), leading to the expression of
early (E) genes, including those required for genome replication,
and late (L) genes including structural proteins (Yuan et al., 2006).
We and others have previously reported the quantitation of
EBV transcripts in both in vitro models and in ex vivo samples
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using reverse transcriptase quantitative PCR (RT-QPCR) (Bell et al.,
2006; Dorner et al., 2008; Jochum et al., 2012; Kubota et al., 2008;
Kurokawa et al., 2005; Shannon-Lowe et al., 2009; Tierney et al.,
2011; Wang et al., 2009; Whitehurst et al., 2013). However these
earlier studies only quantiﬁed each transcript relative to that in a
reference EBV-infected cell line, with a panel of cell lines being
used for different latent and lytic transcripts. Due to variations in
the efﬁciency of different PCR reactions and the use of different
reference lines, this approach precluded a meaningful comparison
of the absolute levels of viral transcripts within a sample. In the
present work, we have developed an inexpensive, high throughput
method for the absolute quantiﬁcation of EBV transcripts in small
amounts of RNA applicable to a variety of samples including
clinical biopsy material. To this end we designed a reference
plasmid containing a single copy of 45 different latent and lytic
cycle EBV amplicons and 3 cellular control amplicons. Using a
48:48 dynamic array integrated ﬂuidics circuit (IFC) and the
Biomark C system (Fluidigm), we were able to simultaneously
screen 48 samples with up to 48 different Taqman RT-QPCR assays
(Spurgeon et al., 2008). The absolute numbers of each transcript
were then determined from standard curves generated from
known copy numbers of the reference plasmid. In this paper we
have validated this approach and report the quantiﬁcation of EBV
transcripts in different experimental infection models and in
clinical Burkitt lymphoma samples. This analysis lead to a number
of novel observations that are relevant to a more complete
understanding of the transcriptional events following primary
infection of B cells and in cell lines established from normal and
malignant B cells.
Results
Validation of the Fluidigm dynamic array system for EBV transcript
detection
A series of primer and probe combinations were designed for
RT-QPCR ampliﬁcation of 45 EBV amplicons, representing 23 latent
cycle transcripts; 2 immediate-early (IE), 11 early (E), 6 late
(L) transcripts; 3 poorly characterized RNAs (LF1, LF2 and LF3)
and 4 non-coding RNAs (Supplementary Table S1). To determine
the absolute levels of each transcript by RT-QPCR, the reference
AQ-plasmid was synthesized containing a single copy of each of
these amplicons together with sequences recognized by GAPDH,
PGK1 and B2-microglobulin Human Endogenous Control TaqMan
assays (Life Technologies) (Fig. 1A and Supplementary Fig S1).
Following a speciﬁc target ampliﬁcation step, PCR ampliﬁcation
and detection was performed using the Fluidigm Biomark HD and
48:48 dynamic array IFC system (Spurgeon et al., 2008). In a pilot
experiment, tenfold dilutions of the AQ-plasmid were subjected to
12 cycles of pre-ampliﬁcation prior to QPCR with 45 EBV assays
and 3 cellular assays, alongside control plasmid dilutions that had
not been pre-ampliﬁed. Sensitive detection of all the targets was
dependent upon the pre-ampliﬁcation step, as shown by the
failure to detect all but the highest concentration of plasmid in
the non-ampliﬁed controls (Fig. 1B). By contrast, most of the assays
using pre-ampliﬁed samples were able to detect the 10 copies/ml
dilution, with some detecting the 1 copy/ml sample. Fig. 1C shows
a panel of 6 representative standard curves drawn from the
same data: these include a latent transcript, Wp; an immediate-
early (IE) lytic transcript, BZLF1; an early (E) lytic transcript,
BALF1; a late (L) lytic transcript, BILF1; a non-coding transcript,
EBER1; and a cellular transcript, PGK1. The similarity of the slopes
and intercepts indicate comparable sensitivities and PCR ampliﬁ-
cation efﬁciencies, while the correlation values show that
pre-ampliﬁcation did not affect the linearity of the reaction.
Comparison of the Ct values for the same 6 representative genes
obtained from 10 independent experiments demonstrated that the
results from the Fluidigm Biomark HD system were reproducible
across a 4 to 5 log range (Fig. 1D).
Absolute quantitation of EBV transcripts following induction of lytic
cycle
Having validated the method of high-throughput absolute
quantitation using a plasmid control, we next sought to use our
panel of EBV assays to characterize the EBV transcriptome follow-
ing the switch from latency into viral replication. To this end,
Akata-BL cells displaying a predominantly Lat I gene expression
proﬁle were induced into lytic cycle by B cell receptor cross-
linking and cells were harvested at intervals from 0.5 to 72 h for
RNA extraction and RT-QPCR analysis. In the representative
experiment shown in Fig. 2, 69% of cells had entered the lytic
cycle, as judged by ﬂow cytometry of BZLF1-positive cells at 24 h
post-induction (data not shown). The RT-QPCR data shown as
histograms in Fig. 2 are expressed as the number of transcripts/ng
of input RNA. To more readily compare the results between
samples taken at different time points, and to correct for possible
variations in RNA input, cDNA synthesis and pre-ampliﬁcation
efﬁciency, these data were also normalized to levels of cellular
PGK1 transcripts (Fig. 3 and Supplementary Fig. S2).
Untreated Akata-BL cells (0 h) had very low levels of latent
gene transcription and some baseline lytic cycle activity. By 2 h
post-induction, there was a clear increase in the number of BZLF
transcripts, although interestingly the level of the second IE RNA,
BRLF1, was much lower and remained so throughout the time
course. BZLF1 was the most abundant transcript at 4 h post-
induction when levels peaked around 164,000 transcripts/ng
RNA. Several E RNAs were also detectable by this time point, with
BHRF1, BMLF1, BMRF1, BNLF2A and BNLF2B being the most
abundant. With the exception of BNLF2A and BNLF2B, E gene
expression generally continued to rise until 12 h post-induction
and then declined. By contrast, L RNAs were much lower at these
early times. Consistent with a previous report (Yuan et al., 2006), L
gene expression generally peaked at 24 h post-induction although
we noted large variations in transcript copy numbers between
genes. The LF transcripts are less well characterized than other
EBV genes due to their deletion from the B95.8 prototype strain.
While levels of LF1 and LF2 peaked at 12 h post induction
consistent with E gene expression, LF3 only reached maximal
levels at 24 h. Based on these kinetics, LF3 behaves like a L RNA but
in fact has previously been deﬁned as an E RNA because its
expression is not affected by inhibitors of viral DNA replication
(Yuan et al., 2006).
Consistent with previous studies (Amoroso et al., 2011; Rowe et
al., 1992; Yuan et al., 2006), increased latent gene transcription
also was apparent by 24 h post induction, most notably for LMP1,
EBNA2 and LMP2A (Figs. 2 and 3 and Supplementary Fig. S2).
However the most abundant of these, LMP1, was still around 30-
fold lower than the most abundant lytic transcript BVRF2 (cf.
13,000 LMP1 transcripts/ng RNA and 380,000 BVRF2 transcripts/
ng RNA). EBNA1 transcripts also increased following lytic cycle
induction (as measured by assays detecting QUK-, UK- and FUK-
spliced EBNA1 transcripts; Fig. 3 and Supplementary Fig. S2) as a
result of activation of the lytic cycle Fp promoter. However, the
levels of UK- and FUK-spliced transcripts encoding EBNA1
remained very low and, unexpectedly, represented only about
10% of the total Fp-initiated transcription (FU assay, Fig. 3). Thus
our quantitative assays conﬁrm that the majority of FU-spliced
transcripts initiating from Fp do not splice into the EBNA1 open
reading frame (Schaefer et al., 1995a); where these Fp-initiated
transcripts splice to beyond the U exon is presently unknown.
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Fig. 1. Validation of the 48:48 dynamic array RT-QPCR assays for EBV transcripts. (A) Design of the AQ-plasmid. Further details of the sequences are provided in
Supplementary Table S1 and Fig. S1. (B) Heat map summarizing the signals obtained for all 45 PCR assays using 10-fold dilutions of the AQ-plasmids with and without pre-
ampliﬁcation. The scale placed to the right of the heat maps ranges from 3 to 38 Ct. (C) Representative standard curves for 5 EBV transcripts and the PGK cellular transcript.
Also shown are the best-ﬁt equations which indicate the assays have similar sensitivities while the PCR efﬁciencies are between 86% and 99%. (D) The reproducibility of the
assays for the same 6 representative transcripts is illustrated by the results of 10 independent arrays using independently pre-ampliﬁed AQ-plasmid dilutions.
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Absolute quantiﬁcation of EBV transcripts during primary B cell infection
We next sought to use the expanded panel of PCR assays to
more fully characterize and quantify the absolute levels of latent
and lytic viral transcripts during EBV-driven transformation of
primary resting B cells in vitro. CD19-positive B cells were isolated
and infected with the 2089 recombinant EBV strain at an MOI of
100, and cells were harvested at multiple time-points for isolation
of RNA and quantiﬁcation of viral gene transcripts.
While the kinetics and pattern of latent gene expression largely
agreed with published data (Alﬁeri et al., 1991; Allday et al., 1989;
Shannon-Lowe et al., 2005), the absolute numbers of transcripts
revealed some unexpected ﬁndings (Fig. 4A and Supplementary
Fig. S3). At day 1 post infection, the levels of Wp-initiated and
EBNA2-speciﬁc transcripts already exceeded 60,000 transcripts/ng
RNA (Fig. 4A) with lower levels (8700 transcripts/ng RNA) of Y2-
HF spliced latent BHRF1 transcripts also present. Notably these
initial levels of Wp-initiated EBNA2 and BHRF1 transcripts were
around 18-fold higher and 3-fold higher, respectively, than the
mean levels in 3 early passage LCLs tested within 3 months post-
infection (Fig. 4A and B). Cp-initiated EBNA transcripts together
with UK-spliced EBNA1 and EBNA3A transcripts, were also detect-
able at day 1 post infection but at much lower levels (Fig. 4A and
Supplementary Fig. S3).
By day 2 post-infection, Wp activity and EBNA2 transcript levels
had started to fall, although they were still by far the most abundant
transcripts, while Cp-initiated transcripts increased and LMP1 was
now detectable. During the remainder of the time course, Wp
activity and EBNA2 and BHRF1 transcript levels continued to fall,
while Cp-initiated transcripts remained unchanged. By day 5, LMP1
levels had reached their maximum and EBER1 RNA became
detectable. By 10 days post-infection the transcription proﬁle, with
the exception of the EBERs, was similar to that of established LCLs
(Fig. 4A and B, Supplementary Fig. S3). Surprisingly even after Wp
activity had declined at later time points, numbers of Wp-initiated
transcripts were still comparable to those of Cp transcripts.
In contrast to latent gene transcription, there were very few
lytic cycle transcripts during primary infection (Figs. 4A, 5 and
Supplementary Fig. S3). Notable exceptions were BNLF2A and
BNLF2B which were detected contemporaneously with, and at
equivalent levels to, LMP1 (Figs. 4A and 5). However BNLF2A and
BNLF2B transcripts are contiguous with the 30 untranslated region
of the LMP1 mRNA and therefore, given the parallels between the
BNLF2 and LMP1 signals, it is likely that the BNLF2 signals
observed here are predominantly due to LMP1 transcripts. Of the
other detectable lytic cycle transcripts, the most abundant was
BZLF1 which peaked at 5 days post-infection (Fig. 4A and
Supplementary Fig. S3). However this BZLF1 signal was at least
100-fold lower than the levels observed during bona ﬁde lytic cycle
(cf. Figs. 2 and 4A), implying that either less than 0.5% of the cells
expressed high levels of BZLF1 or that BZLF1 was uniformly
expressed at very low levels in the entire population.
For comparative purposes, the PGK1-normalized changes in
EBV gene expression during lytic cycle induction in Akata-BL and
during primary B cell infection are shown as heat maps in Fig. 5.
Surprisingly the pattern and levels of Lat III-associated latent
transcripts expressed at late stages of lytic cycle were similar to
those in established LCLs. By contrast the levels of lytic cycle
transcripts induced in productively infected Akata-BL cells sub-
stantially surpassed any lytic gene expression seen in primary
infection or established LCLs. Indeed, the levels of many lytic cycle
Fig. 2. Absolute quantitation of EBV transcripts during induction of lytic cycle.
Akata BL cells were induced into lytic cycle by BCR ligation with anti-IgG. Cells were
harvested at the indicated time-points and RNA isolated for analysis on the 48:48
dynamic array. Levels of individual latent, immediate early (IE), early (E), late
(L) and non-coding transcripts are reported as copies per ng RNA. Data are shown
for one representative experiment and the error bars represent the S.E.M of
3 replicate cDNA samples that were independently pre-ampliﬁed. Note that BHRF1
can be both a latent transcript (with W2-HF and Y2-HF exon structures transcribed
from Cp/Wp) and a lytic transcript (with the H2-HF exon structure transcribed from
a separate promoter).
2 hours
W
p
C
p
E
B
N
A
1-
Q
U
K
E
B
N
A
1-
U
K
E
B
N
A
2
E
B
N
A
3A
E
B
N
A
3B
E
B
N
A
3C
LM
P
1
LM
P
2A
LM
P
2B
B
H
R
F1
 W
2-
H
F
B
H
R
F1
 Y
2-
H
F
B
H
R
F1
 H
2-
H
F
B
ZL
F1
B
R
LF
1
B
M
LF
1
B
M
R
F1
B
A
LF
1
B
A
LF
2
BA
R
F1
B
G
LF
5
B
N
LF
2A
B
N
LF
2B FU
E
B
N
A
1-
FU
K
B
A
LF
4
B
IL
F1
B
IL
F2
BN
R
F1
BV
R
F2
G
p3
50 LF
1
LF
2
LF
3
B
A
R
T1
-3
B
A
R
T 
2-
3
E
B
E
R
1
E
B
E
R
2
0
100000
200000
300000
400000
tra
ns
cr
ip
ts
 p
er
 n
g 
R
N
A
4 hours
W
p
C
p
E
B
N
A
1-
Q
U
K
E
B
N
A
1-
U
K
E
B
N
A
2
E
B
N
A
3A
E
B
N
A
3B
E
B
N
A
3C
LM
P
1
LM
P
2A
LM
P
2B
B
H
R
F1
 W
2-
H
F
B
H
R
F1
 Y
2-
H
F
B
H
R
F1
 H
2-
H
F
B
ZL
F1
B
R
LF
1
B
M
LF
1
B
M
R
F1
B
A
LF
1
B
A
LF
2
BA
R
F1
B
G
LF
5
B
N
LF
2A
B
N
LF
2B FU
E
B
N
A
1-
FU
K
B
A
LF
4
B
IL
F1
B
IL
F2
BN
R
F1
BV
R
F2
G
p3
50 LF
1
LF
2
LF
3
B
A
R
T1
-3
B
A
R
T 
2-
3
E
B
E
R
1
E
B
E
R
2
0
100000
200000
300000
400000
tra
ns
cr
ip
ts
 p
er
 n
g 
R
N
A
8 hours
W
p
C
p
E
B
N
A
1-
Q
U
K
E
B
N
A
1-
U
K
E
B
N
A
2
E
B
N
A
3A
E
B
N
A
3B
E
B
N
A
3C
LM
P
1
LM
P
2A
LM
P
2B
B
H
R
F1
 W
2-
H
F
B
H
R
F1
 Y
2-
H
F
B
H
R
F1
 H
2-
H
F
B
ZL
F1
B
R
LF
1
B
M
LF
1
B
M
R
F1
B
A
LF
1
B
A
LF
2
BA
R
F1
B
G
LF
5
B
N
LF
2A
B
N
LF
2B FU
E
B
N
A
1-
FU
K
B
A
LF
4
B
IL
F1
B
IL
F2
BN
R
F1
BV
R
F2
G
p3
50 LF
1
LF
2
LF
3
B
A
R
T1
-3
B
A
R
T 
2-
3
E
B
E
R
1
E
B
E
R
2
0
100000
200000
300000
400000
tra
ns
cr
ip
ts
 p
er
 n
g 
R
N
A
24 hours
W
p
C
p
E
B
N
A
1-
Q
U
K
E
B
N
A
1-
U
K
E
B
N
A
2
E
B
N
A
3A
E
B
N
A
3B
E
B
N
A
3C
LM
P
1
LM
P
2A
LM
P
2B
B
H
R
F1
 W
2-
H
F
B
H
R
F1
 Y
2-
H
F
B
H
R
F1
 H
2-
H
F
B
ZL
F1
B
R
LF
1
B
M
LF
1
B
M
R
F1
B
A
LF
1
B
A
LF
2
BA
R
F1
B
G
LF
5
B
N
LF
2A
B
N
LF
2B FU
E
B
N
A
1-
FU
K
B
A
LF
4
B
IL
F1
B
IL
F2
BN
R
F1
BV
R
F2
G
p3
50 LF
1
LF
2
LF
3
B
A
R
T1
-3
B
A
R
T 
2-
3
E
B
E
R
1
E
B
E
R
2
0
100000
200000
300000
400000
tra
ns
cr
ip
ts
 p
er
 n
g 
R
N
A
Latent Lytic
IE E LE
Non-coding
0 hours
W
p
C
p
E
B
N
A
1-
Q
U
K
E
B
N
A
1-
U
K
E
B
N
A
2
E
B
N
A
3A
E
B
N
A
3B
E
B
N
A
3C
LM
P
1
LM
P
2A
LM
P
2B
B
H
R
F1
 W
2-
H
F
B
H
R
F1
 Y
2-
H
F
B
H
R
F1
 H
2-
H
F
B
ZL
F1
B
R
LF
1
B
M
LF
1
B
M
R
F1
B
A
LF
1
B
A
LF
2
BA
R
F1
B
G
LF
5
B
N
LF
2A
B
N
LF
2B FU
E
B
N
A
1-
FU
K
B
A
LF
4
B
IL
F1
B
IL
F2
BN
R
F1
BV
R
F2
G
p3
50 LF
1
LF
2
LF
3
B
A
R
T1
-3
B
A
R
T 
2-
3
E
B
E
R
1
E
B
E
R
2
0
100000
200000
300000
400000
tra
ns
cr
ip
ts
 p
er
 n
g 
R
N
A
R.J Tierney et al. / Virology 474 (2015) 117–130120
transcripts exceeded even that of the EBER RNAs which were
hitherto regarded as being the most abundant EBV transcripts.
EBV mRNA within infectious virions
It has been reported that EBV transcripts may be packaged into
virus particles and subsequently be transferred to target B cells
during primary infection in vitro (Jochum et al., 2012). To test this
observation, we determined both the number of RNA transcripts
and EBV DNA genomes present in virus preparations which had
been puriﬁed by density gradient centrifugation (Table 1). While
many viral transcripts were detectable using our assays, they were
present at very low copy numbers with the most abundant being
Gp350 RNA (0.007 transcripts/EBV genome). This would suggest
that when primary B cells are infected at a multiplicity of infection
of 100, on average less than one Gp350 transcript is available for
delivery per cell. However this is likely to be a considerable
overestimate, as most of the virus remains at the cell surface with
the majority of infected cells receiving less than 5 genomes, even
at a high multiplicity of infection (Shannon-Lowe et al., 2005).
Therefore our ﬁndings suggest that incoming virus delivers insig-
niﬁcant amounts of viral transcripts.
Quantitation of virus transcripts in different forms of EBV latency
We next compared the absolute levels of EBV transcripts in a
panel of 8 Lat I BL lines, 5 Wp-restricted BL lines, 5 Lat III BL lines
and 10 Lat III LCLs; note many of these cell lines had previously
been tested by relative gene expression studies using a limited
number of assays (Amoroso et al., 2011). Fig. 6A shows the
absolute numbers of each transcript expressed as copies/ng RNA
from four representative cell lines, while Fig. 6B shows PGK1-
IE transcripts
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Fig. 3. Kinetics of EBV transcript changes during induction of lytic cycle. As in Fig. 2, Akata cells were induced into lytic cycle. Here, the level of EBV transcripts detected in
each sample was expressed relative to the number of cellular PGK transcripts detected in each sample. Error bars represent the S.E.M of 3 replicate cDNA samples that were
independently pre-ampliﬁed.
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normalized data from all 28 lines in the form of a heat map. Mutu I
BL and Mutu III BL are well characterized sub-clones derived from
the same parental biopsy sample but with Lat I and Lat III patterns
of gene expression, respectively (Gregory et al., 1990). Oku-BL is a
Wp-restricted BL line containing both a transcriptionally active
EBNA2-deleted EBV genome and a silent wild-type genome (Kelly
et al., 2002), while Oku-LCL was derived by in vitro transformation
of normal B cells with the wild-type Oku virus.
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Fig. 4. Absolute quantitation of EBV transcripts induced during infection of normal B cells. (A) Primary B cells isolated from peripheral blood were infected at an M.O.I. of 100
with the 2089 recombinant EBV derived from B95.8 strain. Cells were harvested at the indicated time-points and RNA isolated for analysis on the 48:48 dynamic array. Levels
of transcripts were measured as number of transcripts per ng RNA, and the data are shown for one representative experiment. Error bars represent the S.E.M of 3 replicate
cDNA samples that were independently pre-ampliﬁed. (B) For comparison, 3 newly-established LCLs (2–3 months post-infection) were assayed in parallel.
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As expected, the non-coding EBERs were the most abundant
EBV transcript in all cell lines regardless of latency state, and these
data are therefore displayed on separate axes. Although there was
a large variation in the levels of EBER transcripts (63–66,532
transcripts/ng RNA), EBER1 levels were consistently higher (med-
ian, 11,773) than EBER2 (median 946). The non-coding BART RNAs
were also ubiquitously expressed with the BART exon 1–3 spliced
transcript always more abundant (median, 164; range, 2–2535
transcripts/ng RNA) than the exon 2–3 spliced form which was
barely detectable (median, 2; range, 0.0004–47 transcripts/ng
RNA), a result that had been masked in previous studies
(Amoroso et al., 2011) using relative measurements.
Analysis of Lat I BL lines, exempliﬁed by Mutu-I BL (Fig. 6A and
B), conﬁrmed that QUK-spliced EBNA1 transcripts are the most
common antigen-coding latent transcripts in this form of latency
(median 43 transcript/ng; range 14–202). Many lytic cycle RNAs
were also present at levels comparable to EBNA1, which we
presume are generated by a minor subpopulation of lytically
infected cells. However several lytic RNAs were consistently
detected at levels in excess of that which might be explained by
spontaneous reactivation; these included LF3 (median 195 tran-
scripts/ng; range 48–1370), BALF4 (median 171 transcripts/ng;
range 8–558) and BILF1 (median 168 transcripts/ng; range 14–
433), (Fig. 6B and Supplementary Fig. S4).
Wp-restricted BL lines are characterized by the presence of an
EBNA2-deleted genome and the expression of EBNA-LP, BHRF1,
EBNA1 and the EBNA3 family of genes, all driven from Wp, and
expression of the EBER and BART RNAs (Kelly et al., 2006, 2009). In
the representative Wp-restricted Oku-BL cell line (Fig. 6A) there
were almost 5000 Wp-initiated transcripts/ng RNA; W2-HF
spliced BHRF1 transcripts were the most abundant component of
these Wp-initiated transcripts. A similar situation was found in the
other Wp-restricted BL lines, as clearly shown on the heat map
(Fig. 6B). Only the EBER RNAs ever reached such consistently high
levels of transcription. In contrast the other transcripts present in
Wp-restricted latency, EBNA1, EBNA3A, EBNA3B, and EBNA3C,
were expressed at much lower levels.
Lat III lines are characterized by the transcription of all six
EBNAs (either from Cp and/or Wp), LMPs, BARTs and EBERs. The
representative Lat III lines, Mutu-III BL and Oku-LCL (Fig. 6A), show
a dominance of Cp-initiated transcripts over Wp-initiated tran-
scripts that was a characteristic of most Lat III lines; a notable
exception in our series was the X50-7 LCL, which is unusual in
having a genomic deletion encompassing Cp (Yandava and Speck,
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Fig. 5. Heat maps to compare EBV transcript levels during lytic cycle induction and infection of primary B cells. Heat map summarizing and comparing the EBV transcription
proﬁles obtained from the experiments described in Figs. 2 and 4. The data are expressed as number of EBV transcripts relative to PGK transcripts, as indicated by the scale to
the right of the heat map. Each color change indicates a two-fold increment in transcript levels. Assays affected by polymorphisms or by deletions in the viral genome are
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1992). In all Lat III lines, EBNA2 and latent BHRF1 (Y2-HF splice)
transcripts were the principal products of the Cp/Wp promoters.
As noted in the other forms of latency, relatively few EBNA1 and
EBNA3A, -3B and -3C transcripts were detected, whereas LMP1
and LMP2 transcripts were more abundant and were often
detected at levels comparable to EBNA2 transcripts.
Verifying the low number of EBNA1 transcripts per cell
Whilst EBNA1 transcripts were readily detected in all EBV-
positive cell lines, our data suggest that there might be as little as
1 transcript per cell in some cases, assuming that a typical cell
contains about 30–35 pg RNA. To investigate this more accurately,
we sorted between 1 and 100 cells directly into replicate wells of a
PCR plate and then subjected the samples to pre-ampliﬁcation and
RT-QPCR without prior isolation of RNA. Using linear regression
analyses of data from three LCLs and two Lat I BL lines, the mean
number of UK-spliced EBNA1 transcripts was 7.071.5 transcripts
per cell (Supplementary Table S2). In the same experiments, we
observed an average of 154730 cellular PGK transcripts per cell.
As the level of PGK transcripts appears relatively constant between
different lines and different EBV latencies, this result was used to
estimate the approximate number of all viral transcripts per cell
from the previously determined ratio of EBV transcripts to PGK
transcripts; this conversion has been applied to the scale of the
heat maps shown in Fig. 6B and in Supplementary Table S3.
Quantifying EBV transcripts in Burkitt lymphoma biopsies
One feature of the Dynamic Array RT-QPCR method is that only
a very small volume of sample is required to generate quantitative
transcription data for 48 individual QPCR assays. This allowed us
to examine a series of seven African BL biopsy samples for which
very limited amounts of material were available. The data for
5 samples, expressed as transcripts/ng of input RNA, are shown on
histograms in Fig. 7A and the PGK1-normalized data for all seven
samples are shown in the heat maps in Fig. 7B.
Three observations can be made from these biopsy data. First,
the gene expression patterns in the BL biopsies are broadly
consistent with those observed with derived BL lines (cf Figs. 6B
and 7B), with the Wp, BHRF1 and QUK expression proﬁles readily
distinguishing between Lat I and Wp-restricted forms of BL. Second,
the striking similarity between the PGK1-normalized data for BL
lines and biopsies included the detection of BALF4, BILF1 and LF1–3
transcripts at levels that were consistently higher than the other
lytic cycle transcripts. Third, in contrast to most BL lines, LMP2
expression was readily detectable in all seven biopsies, in some
cases at levels comparable to those seen in LCLs (cf. Figs. 6B and 7B).
LMP2A transcripts have previously been observed in some BL
biopsies using non-quantitative end-point PCR assays (Tao et al.,
1998), but our data suggest that their expression may be a more
consistent feature of BL tumors than is apparent in derived BL lines.
Discussion
In this study, we have optimized and validated the high
throughput Fluidigm Dynamic Array system to simultaneously
quantify 48 EBV and cellular transcripts in up to 48 RNA samples.
This platform is ﬂexible such that individual QPCR assays can
easily be substituted according to the needs of a particular
experiment and expanded to a 9696 format if screening for
additional transcripts is required in the future. While PCR-based
array proﬁling of KSHV and EBV transcripts in primary Kaposi
sarcoma lesions and virus-positive cell lines has been reported
previously (Dittmer, 2003; Fakhari and Dittmer, 2002; Kurokawa
et al., 2005; Wang et al., 2009; Whitehurst et al., 2013), the present
work provides two novel features. First, the Fluidigm system
requires very little starting material (less than 25 ng RNA) making
it suitable for analyzing small clinical samples. Second, we have
developed a common standard that allows absolute quantiﬁcation
of transcript numbers rather than measuring EBV transcript levels
relative to their expression in a panel of reference cell lines.
Due to developments in sequencing technologies, RNA-Seq is
rapidly becoming the gold standard method for gene expression
proﬁling, and two recent RNA-Seq studies have characterized in
detail the EBV transcriptome in Lat I BL cells (Concha et al., 2012;
Lin et al., 2010). In contrast to our QPCR approach, RNA-Seq can
identify both previously characterized EBV transcripts and novel
viral transcripts. However for most laboratories RNA-Seq remains
prohibitively expensive for screening EBV transcription in large
panels of samples. Another limitation of RNA-Seq is that tran-
scripts derived from repetitive sequences (which constitute as
much as 20% of the EBV genome) cannot be reliably mapped and
quantiﬁed; these include the 50 regions of the Cp/Wp-initiated
transcripts and LF3 transcripts. The Dynamic Array platform used
in the present study is not intended to compete with RNA-Seq,
rather it is a complementary approach that represents a relatively
low-cost option for high-throughput, sensitive, and reliable simul-
taneous assay of multiple EBV transcripts from small amounts of
material.
One striking observation from our analyses of EBV transcription
was the low levels of EBNA1 transcripts. Typically, there appear to be
Table 1
EBV mRNAs detected in mature infectious virions.
Transcript Number of transcripts
per ml RNAa
Number of transcripts per virion b
Wp 38 o
Cp 5 o
QUK 0 o
UK 47 o
FU 28 o
FUK 0 o
EBNA2 1,381 o
EBNA3A 9,240 0.003
EBNA3B 5,791 0.002
EBNA3C 305 o
LMP1 0 o
LMP2A 10,280 0.004
LMP2B 5,717 0.002
W2-HF 0 o
Y2-HF 0 o
H2-HF 292 o
BZLF1 10,594 0.004
BRLF1 6,325 0.002
BMLF1 14 o
BMRF1 2,548 0.001
BALF1 5,099 0.002
BALF2 3,187 0.001
BARF1 5,547 0.002
BGLF5 3,475 0.001
BNLF2A 11,064 0.004
BNLF2B 7,826 0.003
BALF4 5,261 0.002
BILF1 6,077 0.002
BILF2 5,530 0.002
BNRF1 4,354 0.002
BVRF2 6,626 0.002
Gp350 19,150 0.007
EBER1 9,013 0.003
EBER2 7,058 0.003
a Corresponds to input from 2.7106 virions.
b o Indicates values less than 0.001 transcripts/virus genome.
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Fig. 6. Quantitation of EBV transcripts in B cell lines displaying different forms of latency. (A) Array data obtained from 3 representative BL lines displaying different forms of
latency and from an LCL established by infection of normal B cells with the strain of EBV isolated from Oku BL. Results are expressed as number of EBV transcripts per ng RNA.
(B) Heat map of data obtained from 8 Lat I BL lines, 5 Wp BL lines, 5 Lat III BL lines, and 10 LCLs. For comparison, results for sorted 100% lytically infected AKBM cells are also
shown in the rightmost column. The heat maps were generated exactly as in Fig. 5.
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Fig. 7. Quantitation of EBV transcripts in BL biopsy samples. (A) Array data obtained from 5 BL biopsy samples; results are expressed as number of EBV transcripts per ng
RNA. (B) Heat map summary of array data obtained from all 7 BL biopsies.
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fewer than 10 EBNA1 transcripts per cell (and some cases only
1 transcript per cell) both in Cp/Wp-using virus-transformed B cells
and Qp-using malignant BL tumor cells. Actually, this is in agree-
ment with previously reported RNA-Seq data (Lin et al., 2010)
obtained from two representative Lat I BL lines, Mutu-I BL and
Akata BL, both of which are included in our present study. EBNA1
transcription has been reported to occur transiently during cell
division (Chau et al., 2008; Davenport and Pagano, 1999), which may
in part explain the very low average steady state levels of transcripts.
Nevertheless, EBNA1 protein is detectable at constant levels at all
stages of the cell cycle due to its very long half life, which can be in
excess of 48 h (Davenport and Pagano, 1999). Interestingly, the
EBNA3 family transcripts, which are expressed during primary
infection of B cells and in lines displaying Latency III or Wp-
restricted latency, are also present at levels similar to or less
abundant than the EBNA1 transcripts. Again, the EBNA3 proteins
are very stable and have slow turnover rates (Touitou et al., 2005).
Notably, a global quantitation of cellular mRNA and protein copies/
cell (Schwanhausser et al., 2011) suggests that genes with steady
state levels of less than 10 transcripts/cell may still produce between
102 and 107 steady state copies of protein. Moreover there does not
seem to be a simple correlation between the number of mRNA and
protein molecules, and neither does the protein half-life necessarily
predict how many copies of protein might be produced from a small
number of mRNA copies; an extreme example is Histone H1.2, which
has an average of 4.3 copies of mRNA and 1.8107 copies of protein/
cell (Supplementary Table S3).
Our assays of primary B cell infection conﬁrmed the well
established time course of Wp-initiated EBNA2 and BHRF1 tran-
scription, followed by activation of Cp and transcription of the
remaining EBNAs and LMPs (Alﬁeri et al., 1991; Shannon-Lowe
et al., 2005; Woisetschlaeger et al., 1990). In contrast to an earlier
study (Jochum et al., 2012), our data (Table 1) suggest that virion-
delivered EBV RNAs do not signiﬁcantly contribute to the levels of
these initial transcripts. We speculate that these contradictory
ﬁndings may be explained by exosome contamination in unpur-
iﬁed virus preparations used in the previous study, since it is
reported that exosomes secreted from EBV-positive B cells contain
EBV-encoded RNAs, including EBERs and miRNAs (Ahmed et al.,
2014; Pegtel et al., 2010).
A second unexpected observation from our quantitative ana-
lyses of primary B cell infection concerned the levels of Cp/Wp-
derived transcripts. Wp-initiated transcripts and EBNA2 encoding
transcripts were remarkably high at day 1 post infection, con-
siderably higher than found in established LCLs, which is consis-
tent with the activation of multiple copies of Wp driving their
transcription (Tierney et al., 2011). The subsequent switch to EBNA
transcription from the single copy Cp promoter results in the
lower stable levels of EBNA2 transcripts in the outgrowing LCLs.
Although Cp-initiated transcription increases temporally as Wp-
initiated transcription wanes, what was not appreciated from
previous studies was that even when the levels of Wp transcripts
have declined to the minimal levels observed in LCLs, their
number is still comparable to, and sometimes exceeds, the number
of Cp-derived transcripts. This observation necessitates a rethink
of the relative importance of Cp and Wp promoter usage in
establishing persistent latent infection.
Our data also allow us to comment on the expression of lytic
cycle genes during EBV transformation of B cells. Although virion-
delivered transcripts may be negligible (Table 1), it is clear that
lytic cycle transcription does occur following primary infection of
B cells (Kalla et al., 2010; Shannon-Lowe et al., 2009; Wen et al.,
2007). Consistent with previous reports, BZLF1 was the most
abundant lytic cycle gene with a burst of transcription starting
between day 4 and day 6 post infection. However the PGK1-
normalized BZLF1 transcript level at day 5 post-infection was 300-
fold less than that of productively-infected Akata-BL cells; at
present we cannot distinguish whether these signals are derived
from a very small number of infected cells undergoing sponta-
neous reactivation or a general low level of BZLF1 transcription in
all the culture. However the lower amounts of other lytic cycle
transcripts detected during B cell transformation would indicate
that the cells are not in full productive cycle at this stage,
consistent with published data that infectious virus does not
become detectable until after 13 days post-infection (Kalla et al.,
2010). The failure to initiate full lytic cycle immediately post-
infection is likely a result of the lack of CpG methylation on the
incoming EBV genome, as binding of the BZLF1 transactivator to
several lytic cycle promoters is dependent on DNA methylation
(Bergbauer et al., 2010; Kalla et al., 2010, 2012).
Interestingly, our analyses indicated that certain lytic cycle
genes were in fact more widely expressed than previously recog-
nized during latency (Supplementary Figs. S3 and S4). These
included the vBcl2 homologue BHRF1 which is expressed at low
levels during primary infection of B cells and in Latency III LCLs,
and at much higher levels in the Wp-restricted subset of BLs
carrying an EBNA2 gene-deleted EBV genome (Kelly et al., 2009).
BHRF1 has been postulated to act together with BALF1 to protect B
cells from apoptosis during primary infection (Altmann and
Hammerschmidt, 2005; Kalla and Hammerschmidt, 2012). In our
hands, however, whilst BHRF1 transcripts were readily detected as
early as day 1, BALF1 transcripts were undetectable at this time
point and, when detected at later time-points, were typically at
around 100-fold lower amounts than BHRF1.
We also detected several other lytic cycle genes in one or more
types of latency at levels that could not be accounted for by
contamination with a minor subpopulation of productively
infected cells; these included LF3, BALF4, BILF1 and, to a lesser
extent, LF1 and LF2 (Supplementary Fig. S4). These genes appeared
to be expressed even during Lat I infection in BL lines. Using RNA-
Seq, Lin et al. reported that LF3 was the most abundant EBV
transcript in Lat I BL lines, at levels higher than 98% of cellular
transcripts (Lin et al., 2010). Although we found LF3 to be robustly
expressed in Lat I BL, we did not observe such high levels as
described by Lin et al. This discrepancy is likely due to LF3 being
partially encoded by the IR4 repeat; while our PCR assay was
designed to detect the unique region of the LF3 transcript, RNA-
Seq reads of the IR4 repeat sequences may greatly overestimate
the frequency of LF3 transcripts. The biological signiﬁcance of LF3
and BALF4 expression in latent infection are still unclear. On the
other hand, the expression of BILF1 in latency is intriguing as this
gene encodes a constitutively active vGPCR with oncogenic poten-
tial (Beisser et al., 2005; Lyngaa et al., 2010; Paulsen et al., 2005).
This study also validates the applicability of our high-
throughput assays for analyzing EBV gene expression in small
amounts of RNA isolated from ex vivo tumor biopsies. Similar to BL
cell lines, the biopsy samples consistently contained higher than
expected amounts of LF1, LF2, LF3, BILF1 and BALF4 transcripts. In
addition, LMP2A and, in some cases, LMP2B transcripts were
expressed in BL biopsies at signiﬁcant levels in the absence of
Cp/Wp driven EBNA, or LMP1 transcripts. The detection of LMP2
RNA in BL biopsies has been previously reported (Bell et al., 2006;
Niedobitek et al., 1995; Xue et al., 2002), although LMP2 protein
expression has not been reported, possibly due to a relatively poor
afﬁnity of the available antibodies. Given the known functions of
LMP2A, which include signaling through the BCR pathway and
modulation of cell death and proliferation in experimental models
(Caldwell et al., 1998; Mancao and Hammerschmidt, 2007), its
expression in BL would be consistent with the properties of
this tumor.
The results with the panel of BL biopsy derived RNA samples,
including one sample from a Wp-restricted tumor, Avako, is of
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particular interest to us as it conﬁrms that our method has the
potential to be applied to high-throughput screening of clinical
material to identify the true frequency of Wp-restricted BL tumors
and to correlate the results with clinical outcome. A remarkable
consequence of Wp-restricted latency in BL lines is that it confers a
substantial anti-apoptotic phenotype relative to Latency I BL lines
(Kelly et al., 2005). It is reasonable to presume, but has not yet
been tested, that Wp-restricted and Latency I BL tumors might
differ in clinical presentation and responses to therapy.
Materials and methods
Cell culture
The cell lines used in this work were: Latency I (Lat I) Burkitt
lymphoma-derived cell lines Rael-BL, Ezema-BL, Sav-BL, Dante-BL,
Awia-BL, Kem-BL, MutuI-BL and Akata-BL; the Wp-restricted BL
lines Oku-BL, Awia-BL, Avako-BL, Daudi-BL and Salina-BL; the Lat
III BL lines MutuIII-BL, Namalwa-BL, Raji-BL, Ag876 and Glor-BL;
the long term Lat III virus-transformed 2089 LCL, BZLF1KO LCL,
X50-7 LCL, Oku-LCL, Awia-LCL, IM51.1 LCL and IM 81.1 LCL and
three recently established LCLs generated using 2089 virus
(Amoroso et al., 2011; Kelly et al., 2005). Two other lines derived
from Akata-BL were also used: Akata-GFP-BL is derived from the
re-infection of EBV-loss Akata-BL cells with a recombinant Akata
virus constitutively expressing green ﬂuorescent protein (GFP)
(Kanda et al., 2004) while AKBM cells contain a stably transfected
GFP reporter under the control of the early BMRF1 promoter
(Ressing et al., 2005). Cell lines were maintained in exponential
growth in RPMI supplemented with 10% fetal calf serum and 2 mM
glutamine at 37 1C in 5% CO2.
Biopsy samples
RNA was obtained from a series of previously-described ende-
mic BL tumor biopsies obtained from the West Nile region of
Uganda (Bell et al., 2006; Habeshaw et al., 1999). The use of patient
samples was approved by The West Midlands and The Black
Country Committee of the National Research Ethics Service, UK
(REC reference 14/WM/0001).
Reactivation of EBV in Akata cells and isolation of cells in the lytic
cycle
Akata-GFP-BL cells were induced into lytic cycle by crosslinking
surface immunoglobulin with goat anti-human IgG antibody
(Ressing et al., 2005). Aliquots of 3106 induced cells were
harvested at the indicated time points after the initial addition
of antibody. At 24 h post induction an aliquot of cells was also
subjected to staining with BZLF1-speciﬁc antibody and analyzed
by ﬂow cytometry to determine the percentage of the cell
population that had entered into lytic cycle. To purify productively
infected cells, AKBM cells were induced into lytic cells by IgG
cross-linking and GFP-positive cells were isolated using a MoFlo
cell sorter (Beckman Coulter).
Primary B cell infection
B cells were isolated from apheresis cones (NHS Blood and
Transplant) by positive selection with CD19 Dynabeads (Life
Technologies) followed by removal of the beads with Detachabead
(Life Technologies). B cells were then infected with recombinant
2089 EBV at 100 MOI as previously described (Shannon-Lowe
et al., 2005) and cells harvested at speciﬁc time points, washed,
pelleted and frozen at 80 1C.
Preparation of EBV virions
Virus preparations were made from 293 cells containing the
2089 EBV recombinant virus co-transfected with BZLF1 and BALF4
expression plasmids (Shannon-Lowe et al., 2005). Supernatant
medium was harvested after 3 days, passed through a 0.8 mm
ﬁlter and the virus particles puriﬁed by density gradient centrifu-
gation through Optiprep medium (Axis-Shield). Virion concentra-
tion was determined by real-time Taqman PCR for the EBV Pol
gene, as previously described (Shannon-Lowe et al., 2005). For
RNA isolation, the sample was pre-treated with RNAse and DNAse
I to remove any non-encapsidated nucleic acids prior to RNA
extraction from the virion particles.
RNA extraction and cDNA synthesis
Aliquots of up to 1 mg RNA, prepared using a Nucleospin II kit
(Macherey-Nagel), were subjected to an additional DNAse I treat-
ment using a DNA-free kit (Life Technologies) according to the
manufacturer’s instructions. cDNA was made from up to 1 mg RNA
using QScript (VWR) according to the manufacturer’s protocol and
generally diluted to 20 ng/ml.
Plasmid for absolute quantitation (AQ)
A 4951 base pair DNA sequence was designed containing 45
contiguous latent and lytic EBV amplicons and 3 cellular amplicons
(Supplementary Fig. S1). In cases where the primer-probe combi-
nation ampliﬁed a single exon, the native EBV sequence was used
as the target amplicon. In cases of alternatively spliced viral
transcripts which shared one or more common exons (W0-W1-
W2 and C1-C2-W1-W2 spliced Wp/Cp transcripts, FQ-U-K/Q-U-K/
U-K spliced EBNA1 RNA, W2-HF/Y2HF/H2-HF BHRF1 RNA and
exon 1–3/exon 2–3 spliced BART RNA), composite target
sequences were designed containing the appropriate primer-
probe binding sites and which generated PCR products of a similar
size to the native EBV transcript (Fig. 1A and Supplementary Fig.
S1). In addition, for EBNA2 and LMP1, two alternative amplicons
representing common EBV sequence variants were included. This
sequence was commercially synthesized and inserted into the
pUC57 vector (GenScript) and termed the AQ-plasmid. Serial
dilutions of the AQ-plasmid in the range 101–105 copies/ml were
subsequently used to generate QPCR standard curves.
Design of TaqMan real-time PCR assays
Forty ﬁve primer-probe combinations to detect selected EBV
transcripts were designed using Primer Express (Life Technologies)
under the default parameter settings. All primer-probe sequences
(detailed in Supplementary Table S1) were based on the B95-8
reference genome (de Jesus et al., 2003) and were chosen to avoid
reported EBV sequence variations. In the case of assays which
detect a single exon, the assay name refers to the gene location of
the primer-probe combination. Primer-probe combinations to
detect alternatively spliced transcripts spanned a splice junction
and are referred to both by the gene name and exon structure.
Several of these assays have been described previously (Amoroso
et al., 2011; Bell et al., 2006; Croft et al., 2009; Kelly et al., 2009).
Note that due to a number of overlapping transcription units in the
EBV genome, several assays may potentially detect more than one
transcript. These are BNLF2A and BNLF2B, which may also detect
the 30 UTR of LMP1 transcripts; BMRF1 which may also detect
overlapping BaRF1 transcripts and BNRF1 which may detect the 30
UTR of LMP2 transcripts. Primers were obtained from Alta
Bioscience, University of Birmingham and FAM-TAMRA labeled
TaqMan probes were obtained from Eurogentec. Endogenous
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control assays for Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, assay ID hs99999905.m1 FAM/TAMRA), Beta-2-
microglobulin (B2M, assay ID hs00187842 FAM/TAMRA) and
Phosphoglycerate kinase 1 (PGK1, assay ID hs99999906.m1 FAM/
TAMRA) were obtained from Life Technologies.
Speciﬁc target ampliﬁcation and 48:48 dynamic array IFC analysis
Speciﬁc target ampliﬁcation (STA) was carried out on 1.25ml
(25 ng) of DNAse I-treated RNA with 2.5 ml of 2 TaqMan PreAmp
Master Mix (Life Technologies) and 1.25 ml 0.2 primer mix (45
EBV and 3 cellular 20 TaqMan assays diluted in DNA Suspension
Buffer (10 mM Tris, pH 8.0, 0.1 mM EDTA). Reactions were sub-
jected to 95 1C for 10 min, followed by 12 cycles of 95 1C for 15 s
and 60 1C for 4 min. These pre-ampliﬁed samples were then
diluted 1:5 with DNA Suspension Buffer prior to array analysis,
except for virion samples which were not diluted. For absolute
quantiﬁcation 1.25 ml aliquots of ten-fold dilutions of AQ-plasmid
standards (105–101 copies/ml) were also subjected to the same
pre-ampliﬁcation and dilution steps. The 48:48 dynamic array IFC
was prepared and run in a Biomark HD instrument according to
manufacturer’s instructions using the standard v1 protocol, and
the data were analyzed using Biomark Real-Time PCR Analysis
Software Version 2.0 (Fluidigm).
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